Background: Matrix metalloproteinase (MMP)-3, also known as stromelysis-1, is expressed in inflamed synovium of patients with rheumatoid arthritis (RA). It degrades components of articular cartilage, such as proteoglycans. In Japan MMP-3 has been used as a clinical biomarker of joint destruction and its predictive value for radiographic progression has been reported. Objectives: W aimed to confirm a relation between baseline MMP-3 and radiographic progression at 1 year and to examine the association of the MMP-3 level with ultrasonography (US) findings. Methods: A total of 259 (213 women) consecutive patients with RA were enrolled. We collected baseline data, that included the patient's age, sex, disease duration, use of glucocorticoid or disease modifying antirheumatic drugs, Disease Activity Score-28, and modified total Sharp score (mTSS); MMP-3 and, C reactive protein levels;, rheumatoid factor or anti-citrullinated peptide antibody status,; and the power doppler score (PD) of US assessment of digits and wrists. Baseline MMP-3 level was analyzed in association with the baseline PD value and changes ( ) in mTSS, erosion score ( ERN), joint space narrowing ( JSN) at 1 year from baseline by Pearson's correlation method. Correlations between MMP-3 and mTSS, or PD were also analyzed. Multiple regression analysis was performed, with mTSS as the outcome for baseline variables. Statistical analysis was performed separately by sex because the upper normal limits of MMP-3 differ between the sexes (men ≤121ng/ml, women ≤59.7 ng/ml). Results: There was a weak correlation between the baseline MMP-3 level and baseline PD score in men. There was also moderate correlations between baseline MMP-3 level and structural damage at 1 year only in men. There was no predictive value for baseline MMP-3 level in women in terms of structural damage at 1 year. Multiple regression analysis revealed that the baseline MMP-3 level correlated independently with the mTSS only in men (p=0.0031), whereas in Background: Anti-cyclic citrullinated peptide antibodies (Anti-CCP Ab) are wellestablished serological markers that show high sensitivity and specificity in diagnosing early rheumatoid arthritis (RA). Furthermore, Anti-CCP Ab is reported to be associated with bone erosions of RA. Therefore, Anti-CCP Ab positive RA patient can be a candidate for intensive treatment. Objectives: Upper measurement limit of Anti-CCP Ab increased recently up to 1200 units. High level of Anti-CCP Ab may be a predictor of the profound therapy for RA. To understand the importance of Anti-CCP Ab level, we evaluated RA patients with high titer Anti-CCP Ab in relationship to the other activity markers of RA and the intensity of the treatment for RA. Methods: Total of 186 RA patients with Anti-CCP Ab higher than 30 units was included in this study. Baseline markers such as CRP, MMP-3, RF and anti-CCP Ab were measured at the entry of the study. Relationship among these markers ware evaluated and examined using statistical significance for the single-factor ANOVA and the multiple comparisons. Among those cases 131 cases were treated conservatively with biologics and/or DMARDs and were followed up more than one year. We graded them from I to IV by the intensity of the treatment. Grade I: Biological agent. Grade II: Methotrexate (MTX) more than 12mg or combination with more than 3 DMARDS Grade III: MTX 6-11mg or combination with two recommended DMARDS Grade IV: single use of DMARDS including MTX less than 5mg. Results: There was no relationship between titers of Anti-CCP Ab and titers of RF. We found significant statistical correlation between anti-CCP antibody titers and inflammatory markers such as CRP and MMP-3. There was significant statistical correlation between CRP and MMP-3. In terms of treatment intensity, strong intensity group showed high titer of anti-CCP Ab and CRP. Titer of RF and MMP-3 level did not have any relationship with the treatment intensity. In cases treated with biologics, anti-CCP Ab and CRP were significantly higher compared to non-biologic case group. In 80% of cases treated with biologics titer of anti-CCP was more than 200 units. However, non-biologic treatment was continued in more than 50% of cases with anti-CCP Ab higher than 200 units. Conclusions: Even though we treated cases based on the severity of the symptoms of the patient and response in laboratory data, high anti-CCP Ab titers and CRP at the base line were most associated with the treatment intensity after 1 year. The results of our study suggest that the titer of anti-CCP Ab can be better a predictor of the treatment intensity than MMP-3 and RF. Background: Maturation of autoantibody responses has been suggested to be a proxy for disease maturation. Autoantibody responses against post-translationally modified antigens are present in autoimmune diseases and antibodies directed against carbamylated proteins (anti-CarP antibodies) are a marker of RA. AntiCarP antibody analysis in patients with early RA offers the opportunity to estimate whether specific intervention during such early stages of autoantibody development may have an impact on the maturation of the anti-CarP antibody response. Objectives: We assessed the relationship between changes in anti-CarP isotypes and rates of seroconverson to negative in patients with early RA. Methods: In the Assessing Very Early Rheumatoid arthritis Treatment study (AVERT; NCT01142726), patients with early RA were treated with abatacept (ABA)+MTX, ABA monotherapy or MTX alone.
1 Patients in AVERT were anticyclic citrullinated peptide-2 positive at baseline for study entry.
1 In this post hoc analysis, concentrations of anti-CarP isotypes were measured using custom ELISAs. Anti-CarP ELISAs for immunoglobulin (Ig)G, IgM or IgA isotypes were performed in patient serum at baseline, and at Days 85 and 365 on treatment. Baseline levels of each anti-CarP antibody isotype and % seropositivity were comparable across the three treatment arms. Adjusted mean change from baseline was calculated using a longitudinal repeated measures model. Results: At baseline, 51.3, 42.5 and 29.3% of all patients with serum available in AVERT were positive for IgG, IgM (indicative of an ongoing immunoresponse) and IgA anti-CarP isotypes, respectively. Overall, approximatly 65% of patients were positive for at least one anti-CarP antibody isotype. Median % change from baseline (25%, 75%) for anti-CarP isotypes levels from baseline to Days 85 and 365 are shown (Table) . Analysing patients who were positive at baseline for each of the isotypes, we observed that 19/48 (40%), 16/43 (37%) and 11/48 (23%) of the patients positive for the IgG isotype became negative on ABA+MTX, ABA and MTX, respectively, at 1 year. For the IgM isotype, 26/48 (54%), 14/36 (39%) and 15/38 (39%) became negative on ABA+MTX, ABA and MTX, respectively. For the IgA isotype, 12/26 (46%), 10/23 (43%) and 13/31 (42%) became negative on ABA+MTX, ABA and MTX, respectively. Conclusions: Concentrations of all anti-CarP isotypes (IgM, IgA, IgG) were numerically reduced by abatacept+MTX therapy compared with MTX or abatacept alone. Abatacept+MTX trended towards higher rates of seroconversion to negative for all isotypes over 1 year of treatment. These results indicate that the extent of the anti-CarP antibody response can be modulated by intervention with abatacept on background MTX in anti-citrullinated protein antibody-positive patients with early RA. 
